Rondo AG Merges US-subsidiary Rondo-Pak with CGS
News Dec 04, 2015
Rondo AG from the Körber Business Area Pharma Systems has signed an agreement with Contemporary Graphics and Bindery, Inc. (CGS) to merge its U.S. subsidiary Rondo-Pak Inc., with the business of CGS. The merged company, named Rondo-Pak, LLC, will offer a comprehensive portfolio of packaging and printed components for customers operating in complex environments, including the pharmaceutical industry.
Both Rondo-Pak and CGS aim to establish this newly combined business in early 2016. With their sites in Norristown, PA and Pennsauken, NJ, respectively, both companies are ideally located in the heart of the U.S. East Coast pharmaceutical corridor. The merger includes all activities of Rondo-Pak and CGS in the U.S., as well as Rondo-Pak’s additional production site in San Juan, Puerto Rico.
The new company will offer a broader variety of products and full service solutions for customers. In particular, the combined technological resources and production capacities will benefit customers in the critical area of supply chain optimization by offering a comprehensive product portfolio and single source supply.
Both companies’ current businesses are, to a significant extent, complementary. The merged business will offer customers of Rondo-Pak an extended range of printed packaging formats such as inserts, leaflets, medication guides and regulated marketing materials. Customers of CGS will have access to Rondo-Pak’s special folding cartons and packaging system expertise, in addition to CGS’ current range of products. Intelligent buying center management and new, innovative products add further value for customers. Existing offerings from both companies will be continued in their current, market-proven exemplary quality standards and according to legal pre-conditions in the regulated pharmaceuticals market.
Clemens Berger, CEO of Körber Medipak Systems AG, Switzerland, says: “We are pleased to join forces with CGS, especially given the company’s highly esteemed position within the industry. The merged business can build on both partners’ longstanding experience in the market, as well as their very positive reputation with our international customer base.”
Joachim Hoeltz, CEO of Rondo AG, Switzerland, adds: “Our U.S. subsidiary Rondo-Pak is gaining a strong strategic partner. We are looking forward to further strengthening and expanding the partnerships with our common global customers as well as to jointly developing new opportunities.”
Tim Moreton, CEO of CGS, states: “We are looking forward to this joint business approach. Adding value for our customers by offering more customized solutions, excellent services and a comprehensive portfolio of printed components is our key aim for the transaction.”
Victor Dixon, President of Rondo-Pak Inc.: “The merger with CGS is a great step forward in realizing our future business growth strategy. We are adding resources and enhancing our production capacities. This clearly enables us to serve our customers even better.”
The businesses of Rondo-Pak in the U.S. and Rondo AG in Switzerland will remain closely linked. The merged business Rondo-Pak, LLC, is set to play a strategic part in serving the global customers of the Körber Medipak Systems network of companies, especially in the healthcare and pharmaceutical sector.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018